首页> 外文OA文献 >Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.

【2h】

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.

机译：olaparib单药治疗对晚期卵巢癌和三种或更多种先前疗法的种系BRCa1 / 2突变携带者的疗效和安全性。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (gBRCA1/2m) advanced ovarian cancer who had received ≥3 prior lines of chemotherapy. Primary data from this Phase II study (Study 42, ClinicalTrials.govNCT01078662) have been reported previously.

机译：口服聚（ADP-核糖）聚合酶（PARP）抑制剂olaparib的功效和安全性在亚种BRCA1 / 2突变（gBRCA1 / 2m）晚期卵巢癌患者中接受了≥3的先前研究化学疗法。该II期研究（研究42，ClinicalTrials.govNCT01078662）的主要数据先前已有报道。

著录项

作者
Domchek, Susan M; Aghajanian, Carol; Shapira-Frommer, Ronnie; Schmutzler, Rita K; Audeh, M William; Friedlander, Michael; Balmaña, Judith; Mitchell, Gillian; Fried, Georgeta; Stemmer, Salomon M; Hubert, Ayala; Rosengarten, Ora; Loman, Niklas; Robertson, Jane D; Mann, Helen; Kaufman, Bella;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy [J] . Domchek Susan M., Aghajanian Carol, Shapira-Frommer Ronnie, Gynecologic Oncology: An International Journal . 2016,第2期

机译：奥拉帕尼单药治疗晚期卵巢癌种系BRCA1 / 2突变携带者和三株或以上现有疗法的疗效和安全性
2. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety [J] . Matulonis U. A., Penson R. T., Domchek S. M., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第6期

机译：Olaparib单药治疗晚期复发性卵巢癌和生殖系BRCA1 / 2突变的患者：疗效和安全性的多研究分析
3. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [J] . Kaufman Bella, Shapira-Frommer Ronnie, Schmutzler Rita K., Journal of Clinical Oncology . 2015,第3期

机译：Olaparib单药治疗晚期癌症和生殖细胞BRCA1 / 2突变的患者
4. An Integrated Microfluidic Platform for Detecting BRCA1/BRCA2 Gene Mutation and Risk Assessment of Ovarian Cancer [C] . Yu-Hung Cheng, Chih-Hung Wang, Keng-Fu Hsu, International Conference on Solid-State Sensors, Actuators and Microsystems . 2021

机译：一种用于检测BRCA1 / BRCA2基因突变和卵巢癌风险评估的集成微流体平台
5. Dolo?anje Mutacij v Genih BRCA1/2 Iz citolo?kega Materiala Pri Raku jaj?nikov, Jajcevodov in Primarnem Peritonealnem Seroznem Karcinomu =BRCA1/2 mutation testing from cytological samples in patients with ovarian, tubal and primary peritoneal serous cancer [D] . Gornjec, Andreja. 2020

机译：从自我癌症中确定基因Krca1 / 2中的突变吗？
6. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy [O] . Susan M Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, -1

机译：奥拉帕尼单药治疗晚期卵巢癌种系BRCA1 / 2突变携带者和三项或更多先前疗法的疗效和安全性
7. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [O] . Bella Kaufman, Ronnie Shapira-Frommer, Rita K. Schmutzler, 2015

机译：Olaparib患者晚期癌症和种系BRCA1 / 2突变的单一疗法
8. Modifiers of the Efficacy of Risk-Reducing Salpingo-Oophorectomy for the Prevention of Breast and Ovarian Cancer in Carriers of BRCA1 and BRCA2 Mutations [R] . Kauff, N. D. 2008

机译：降低风险的salpingo-Opherectomy用于预防BRCa1和BRCa2突变携带者的乳腺癌和卵巢癌的修饰物

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.

摘要

著录项

相似文献

相关主题

期刊订阅